Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Share-based Compensation (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Share-based Compensation for 15 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 132.45% to $1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.1 million, a 65.95% increase, with the full-year FY2025 number at $6.1 million, up 65.95% from a year prior.
  • Share-based Compensation was $1.7 million for Q4 2025 at Niagen Bioscience, roughly flat from $1.8 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.9 million in Q1 2022 to a low of $735000.0 in Q3 2024.
  • A 5-year average of $1.3 million and a median of $1.3 million in 2021 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: plummeted 34.2% in 2024, then soared 138.91% in 2025.
  • Niagen Bioscience's Share-based Compensation stood at $1.5 million in 2021, then decreased by 9.98% to $1.3 million in 2022, then dropped by 21.79% to $1.0 million in 2023, then fell by 27.48% to $752000.0 in 2024, then soared by 132.45% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Share-based Compensation are $1.7 million (Q4 2025), $1.8 million (Q3 2025), and $1.5 million (Q2 2025).